Effect of Dapagliflozin on IAH in T1DM

Inclusion Criteria: * Type 1 diabetes, disease duration \>1 year * Age \>18 years, \<75 years * BMI 19-40 kg/m\^2 * Insulin treatment according to basal-bolus insulin regimen (injections or insulin pump) * Impaired awareness of hypoglycemia as assessed by a score of 3 or more on the modified Dutch translation of the Clarke questionnaire * Glycated haemoglobin (HbA1c) ≥42 mmol/mol (6%) and ≤75 mmol/mol (9.0%) * Ability to provide informed consent Exclusion Criteria: * Treatment with SGLT-2 inhibitors * Known intolerance to SGLT-2 inhibitors * Treatment with loop diuretics or other anti-hypertensive agents * Treatment with glucose-modifying (other than insulin) or immune-modifying agents (e.g. prednisolon) * Treatment with pioglitazone * Use of statins * A history of cardiovascular disease (e.g. myocardial infarction, stroke, heart failure) or hypotension * A history of galactose-intolerance, lactase deficiency, glucose-galactose malabsorption * History of diabetic ketoacidosis requiring medical intervention within 1 month before screening * Admission to the hospital for hyperglycemia or hypoglycemia within 1 month before screening * Frequent episodes of severe hypoglycemia within 1 month before screening * Laser coagulation for proliferative retinopathy (past 6 months) * Proliferative retinopathy * Diabetic nephropathy as reflected by an albumin-creatinin ratio ˃ 30 mmol/mg or an estimated glomerular filtration rate (by MDRD) ˂60ml/min/1.73m2 * History of pancreatitis (acute or chronic) or pancreatic cancer * Use of premixed insulin or of long-acting insulin alone * Total daily insulin dose requirements \<20 units unless on pump treatment * Pregnancy or unwillingness to undertake measures for birth control